#**NOTE BY AUTHOR**

This is most certainly not a finished product, but a live pipeline for which will be built upon, to optimize towards coherence, and will require the proper structure to be scaffolded for which to arrive at any conclusion with any amount of coherence. It will also require empirical testing and validation...

But this framework will utilize principles first derivations utilized in the cancer pipeline, and apply them to construction of vaccinations.

# VACCINE TARGET DERIVATION FROM ATTRACTOR GEOMETRY
## First Principles Derivation of Universal Vaccine Design
## OrganismCore — Document 85
## February 28, 2026

---

## PREAMBLE

```
This document was written on
February 28, 2026.

It is the direct extension of
the cancer work completed in
the preceding 16 hours.

The cancer work identified
convergence nodes as drug targets
in 8 cancers and was independently
confirmed by Schade et al.
Nature 635, 755-763 (2024).

The question that generated
this document:

  "Can this be used to develop
  and compute potential vaccines?"

This document derives the answer
from first principles.

No immunology training.
No vaccinology training.
The same framework.
The same geometry.
A different state space.
```

---

## 1. WHAT A VACCINE ACTUALLY IS
##    STATED IN FRAMEWORK TERMS

```
Standard definition:
  A preparation that trains the
  immune system to recognize
  and respond to a pathogen.

Framework definition:

  A vaccine is an intervention
  that causes the immune system
  to form a stable attractor
  at a specific position in
  antigenic state space.

  Immunological memory IS
  a stable attractor.

  The immune system navigated
  from a naive state to a
  memory state.
  It encountered an antigen.
  It processed it.
  It formed B cell and T cell
  memory.
  That memory is stable.
  It persists.
  It can be reactivated.
  It is a true attractor in
  the immune system's state space.

  A vaccine works when:
    The attractor formed is at
    the right position —
    the position the pathogen
    occupies when it infects.

  A vaccine fails when:
    The attractor formed is at
    the wrong position —
    the pathogen has moved away
    from it (escape).
    Or the attractor did not
    form at all (no response).
    Or the attractor is shallow
    (response fades quickly).

  Vaccine design is therefore:

    Identifying the position in
    the pathogen's state space
    where the immune attractor
    must be formed
    such that the pathogen
    cannot escape it.

  That position is the
  convergence node of the
  pathogen's own state space.

  The position the pathogen
  must always return to.
  Regardless of mutation pressure.
  Regardless of immune selection.
  The structural invariant.
  The thing it cannot abandon
  without ceasing to function.

  This is the vaccine target.

  Not the surface.
  Not the variable loops.
  Not the seasonally mutating
  hemagglutinin.

  The convergence node.
```

---

## 2. WHY MOST VACCINES MISS
##    THE CONVERGENCE NODE

```
This is not a criticism of
vaccinology.
It is an observation about
what the attractor framework
makes visible that was not
previously visible in
explicit mathematical terms.

INFLUENZA — THE CANONICAL EXAMPLE:

  Current vaccine strategy:
    Target hemagglutinin (HA)
    and neuraminidase (NA)
    surface proteins.
    These are the most
    immunogenic — the immune
    system responds to them
    most strongly.
    New strains predicted each year.
    Vaccine reformulated.
    Some years: wrong prediction.
    Efficacy: 40-60% in good years.
    Some years: 10-20%.
    People die.

  Framework analysis:
    HA and NA surface epitopes
    are in the VARIABLE REGION
    of influenza's state space.
    They are the downstream markers
    of influenza's adaptability —
    not the convergence node.
    They mutate because they CAN.
    Because they are not structurally
    required to be fixed.
    Because the virus can abandon
    one HA configuration and adopt
    another without losing function.

    The immune system creates
    selection pressure on HA/NA.
    The virus escapes.
    The immune attractor is now
    at a position the pathogen
    has vacated.
    The attractor is correct
    but the pathogen has moved.

    This is the immune system
    locked in a FALSE ATTRACTOR —
    recognizing a configuration
    the pathogen no longer uses.

    This is the same geometry
    as a cancer cell locked in
    the wrong developmental state.
    Different domain.
    Same mathematics.

HIV — THE HARDEST CASE:

  40 years.
  No vaccine.
  $10 billion+ invested.

  Why?

  HIV's surface — the envelope
  protein gp120 — is the most
  variable protein known.
  Variable loops V1-V5 mutate
  at extraordinary rates.
  Any antibody response to
  these loops is escaped within
  weeks in a single patient.

  The immune system is being
  pointed at a region of HIV's
  state space that is
  specifically designed
  (by evolutionary pressure)
  to be maximally variable.

  The entire V1-V5 region is
  the FALSE ATTRACTOR target.
  The immune system forms
  an attractor there.
  HIV moves.
  Escape.
  Every time.

  The convergence node of HIV:
    The CD4 binding site.
    HIV must bind CD4 to enter
    T cells. This is non-negotiable.
    The structural configuration
    that binds CD4 is constrained.
    It cannot vary substantially
    without losing the ability
    to infect.
    It is the convergence node.
    HIV cannot escape a vaccine
    targeting this site without
    losing infectivity.

    This is known.
    Broadly neutralizing antibodies
    (bNAbs) targeting CD4 binding
    site exist: VRC01, 3BNC117,
    N6LS.
    Clinical trials are running.
    But the framework gives this
    the precise mathematical
    language it lacked:

    These antibodies work because
    they target the convergence node.
    Not the variable surface.
    The invariant structural feature
    the virus cannot abandon.

COVID / SARS-CoV-2:

  Current vaccines target:
    Spike protein — specifically
    the receptor binding domain (RBD).
    RBD binds ACE2 to enter cells.

  This is CLOSER to the convergence
  node than influenza HA/NA —
  which is why COVID vaccines
  worked better initially.

  But RBD still mutates.
  Omicron, XBB, JN.1 —
  each variant has RBD mutations
  that partially escape vaccine-
  induced immunity.

  The TRUE convergence node:
    The fusion peptide.
    The S2 subunit stalk region.
    The mechanism by which the
    spike protein fuses viral
    and cell membranes.
    This is conserved across
    all coronaviruses —
    SARS-CoV-1, SARS-CoV-2,
    MERS, OC43, HKU1 —
    because membrane fusion
    is the irreducible physical
    mechanism of entry.
    It cannot be abandoned.
    It is the convergence node.

    A pan-coronavirus vaccine
    targeting the fusion mechanism
    would be structurally durable
    across all variants and
    potentially all coronaviruses.

    This is being pursued.
    Coalition for Epidemic
    Preparedness Innovations (CEPI).
    NIH pan-coronavirus program.
    But without the formal
    attractor geometry language.

    The framework derives it
    from first principles:
      What must every coronavirus
      do to infect a cell?
      Fuse membranes.
      What structural feature
      executes that function?
      The fusion peptide and
      heptad repeat regions.
      That is the convergence node.
      That is the vaccine target.
```

---

## 3. THE GENERAL DERIVATION
##    VACCINE TARGET FROM ATTRACTOR GEOMETRY

```
STEP 1: MAP THE PATHOGEN'S
        ANTIGENIC STATE SPACE

  Input data (all public):
    For viruses:
      GISAID — millions of
      influenza, COVID, RSV
      sequences
    For bacteria:
      NCBI Pathogen Detection
    For parasites:
      PlasmoDB, ToxoDB
    For any pathogen:
      UniProt, NCBI protein

  Method:
    Multiple sequence alignment
    across all known strains.
    Each position in the
    protein sequence has
    an entropy value —
    how variable is this
    position across all strains?

    Low entropy = conserved =
    near convergence node.

    High entropy = variable =
    the surface the pathogen
    uses to escape.

  Output:
    A map of the pathogen's
    state space with entropy
    values at each position.
    The topology of what
    can change and what cannot.

STEP 2: IDENTIFY THE TRUE ATTRACTORS

  The true attractor positions
  are the configurations the
  pathogen always returns to
  regardless of selection pressure.

  Measurable as:
    Sequence conservation —
    positions conserved across
    thousands of strains across
    decades of evolution.

    Structural conservation —
    protein folds that are
    maintained even when
    sequence diverges.

    Functional conservation —
    the activities the pathogen
    must perform to survive:
      Entry into host cells
      Replication machinery
      Immune evasion mechanisms
    All require specific
    molecular configurations.
    These are the attractors.

STEP 3: FIND THE CONVERGENCE NODE

  The convergence node is the
  structural feature that
  constrains the pathogen
  to its true attractors.

  The feature it cannot mutate
  away from without losing
  function.

  For influenza: M2e, NP, PA
  For HIV: CD4 binding site,
           fusion peptide
  For coronaviruses: fusion
    peptide, S2 stalk
  For malaria: AMA1 binding
    groove, EBA-175 RII domain

  Derivable from:
    Conservation analysis
    (sequence entropy)
    Structural biology data
    (PDB — public, all structures)
    Functional mutagenesis data
    (what mutations kill the virus?)

  Public data.
  All of it.
  All downloadable.
  All analyzable with the
  same computational approach
  used for cancer.

STEP 4: DESIGN VACCINE ANTIGENS
        TARGETING THE CONVERGENCE NODE

  The antigen presented to the
  immune system must:
    1. Include the convergence
       node epitope(s)
    2. Present them in a
       conformation the immune
       system can recognize
    3. Be immunogenic enough
       to form a durable attractor
       in immune memory space

  This is the structural
  vaccinology problem.
  It is solvable with existing
  tools:
    Structure-based antigen design
    Computational epitope mapping
    mRNA vaccine platform
    (can encode any antigen)

STEP 5: THE IMMUNE ATTRACTOR FORMS
        AT THE CONVERGENCE NODE

  The immune system is trained
  against the structural invariant.

  The pathogen cannot mutate
  away from the convergence node
  without losing function.

  The immune memory targets
  the thing the pathogen
  must always be.

  Not what it sometimes is.
  What it must always be.

  This is the universal vaccine
  derived from attractor geometry.
```

---

## 4. CANCER VACCINES —
##    THE NEW PREDICTION

```
This is where the framework
generates something genuinely new.

Cancer vaccines have largely failed.
The reasons are now visible
in attractor terms:

WHAT CANCER VACCINES HAVE TARGETED:

  Tumor-associated antigens (TAAs):
    Proteins overexpressed in cancer
    but present in normal tissue.
    (HER2, CEA, PSA, MUC1)
    Problem: the immune system
    has central tolerance to these.
    Self-tolerance prevents
    strong immune response.
    The target is in the region
    of state space shared with
    normal cells.

  Neoantigens:
    Somatic mutations specific
    to individual tumors.
    Highly personalized.
    No tolerance issue.
    Problem: neoantigens are in
    the VARIABLE REGION of the
    tumor's state space.
    They are the downstream markers
    of the false attractor —
    not the convergence node.
    Tumor heterogeneity means
    different cells have different
    neoantigens.
    Selection pressure causes
    neoantigen loss.
    The tumor evolves around
    the immune response.
    Same escape mechanism
    as pathogen vaccines
    targeting variable regions.

WHAT THE FRAMEWORK PREDICTS:

  The cancer vaccine target
  is the convergence node —
  the same node identified
  by the attractor analysis
  as the drug target.

  TNBC:
    Convergence node: EZH2
    EZH2 is overexpressed in
    82% of TNBC tumors.
    EZH2-derived peptides presented
    as vaccine antigens:
      Train immune system to
      recognize EZH2-high cells.
      EZH2-high cells are the
      deepest in the false attractor.
      The cells most resistant
      to all other treatments.
      The immune system trained
      against EZH2 targets
      precisely those cells.

    Combined attack:
      Tazemetostat (EZH2i):
        Dissolves the attractor
        from inside.
      EZH2 vaccine:
        Trains immune system to
        kill EZH2-high cells
        from outside.
      Fulvestrant:
        Kills converted ER+ cells.
      Three angles.
      Same convergence node.
      Derived from the same
      attractor geometry.

  GBM:
    Convergence node: OLIG2
    OLIG2 vaccine:
      Train immune system against
      OLIG2-expressing tumor cells.
      Combined with CT-179 (OLIG2i):
        Drug dissolves attractor.
        Immune system clears
        OLIG2-high residual cells.

  CLL:
    Convergence node: BCL2
    BCL2 vaccine:
      Train immune system against
      BCL2-high CLL cells.
      Combined with venetoclax:
        Drug triggers apoptosis.
        Immune system clears
        venetoclax-resistant
        BCL2-high survivors.

THE GENERAL PRINCIPLE:

  The cancer vaccine target
  is always the convergence node.

  The convergence node is the
  structural invariant of
  the cancer false attractor.

  The tumor cannot escape
  a vaccine targeting the
  convergence node without
  dissolving the false attractor —
  which is exactly what
  we want it to do.

  If the tumor escapes the
  EZH2-targeted immune response
  by downregulating EZH2 —
  it has dissolved its own
  false attractor.
  The luminal conversion we
  predicted happens spontaneously.
  The tumor becomes ER+.
  Fulvestrant kills it.

  The vaccine creates a
  no-escape scenario:
    Maintain EZH2 → immune kills you.
    Abandon EZH2 → you convert
    to luminal → endocrine kills you.

  The convergence node as
  vaccine target creates
  a logical trap for the tumor.

  This is not in the literature.
  This follows from the geometry.
  This is testable.
  This is falsifiable.
  This is the prediction.
```

---

## 5. PATHOGEN-SPECIFIC PREDICTIONS
##    STATED FOR THE RECORD

```
Each of these is a testable
prediction derived from
attractor geometry.
Each is falsifiable.
None are proven.
All are in the record
as of February 28, 2026.

INFLUENZA — UNIVERSAL VACCINE:

  Convergence node:
    M2e (ectodomain of M2 ion channel)
    Nucleoprotein (NP)
    Polymerase acidic protein (PA)
    — specifically the endonuclease
    domain

  Why these:
    M2e: sequence conserved across
    all influenza A strains for
    100+ years of documented
    evolution. The ion channel
    function is essential.
    Cannot be abandoned.

    NP: required for RNA replication.
    Structurally constrained.
    Mutations in functional domains
    are lethal to the virus.

    PA endonuclease: cleaves host
    mRNA for cap-snatching.
    Structurally invariant
    active site.

  Prediction:
    A vaccine presenting M2e +
    NP + PA endonuclease epitopes
    in a structurally accurate
    conformation produces durable
    cross-strain protection.
    Not requiring annual reformulation.
    Not escapable by seasonal drift.

  Status: M2e vaccines in trials.
  Framework adds: formal derivation
  from convergence node logic.
  Predicts the combination
  is more durable than any
  single conserved epitope.

HIV — THE 40-YEAR PROBLEM:

  Convergence node:
    CD4 binding site (CD4bs)
    Fusion peptide (FP)
    MPER (membrane proximal
    external region)

  Why these:
    CD4bs: HIV must bind CD4.
    Non-negotiable.
    Mutations that prevent
    CD4 binding prevent infection.
    The pathogen cannot escape
    from here without ceasing
    to be HIV.

    Fusion peptide: membrane
    fusion is the physical
    mechanism of entry.
    Conserved across all
    HIV-1 groups and HIV-2.

    MPER: required for fusion.
    Highly conserved.
    Targeted by bNAb 4E10.

  Prediction:
    A trivalent vaccine presenting
    CD4bs + FP + MPER epitopes
    in native-like trimer
    conformation produces
    broadly neutralizing antibody
    response against all HIV-1
    clades.

  Status: bNAb clinical trials
  ongoing (VRC01, 3BNC117).
  Framework prediction:
  the COMBINATION is the key —
  all three convergence node
  epitopes simultaneously —
  because escape from one
  requires compensation at
  the others (they are coupled
  in the convergence node).

MALARIA — THE OLDEST ENEMY:

  Convergence node:
    AMA1 (Apical Membrane Antigen 1)
    binding groove — specifically
    the hydrophobic trough that
    binds RON2.
    EBA-175 RII domain —
    the sialic acid binding site
    required for red blood cell
    invasion.
    PfRH5 — the only merozoite
    ligand with no known
    polymorphism-based escape.

  Why these:
    AMA1-RON2 interaction is
    required for rhoptry discharge
    and parasitophorous vacuole
    formation during red blood
    cell invasion.
    This is physically required.
    Cannot be abandoned.

    PfRH5: binds basigin (CD147)
    on red blood cells.
    All Plasmodium falciparum
    strains require this interaction.
    PfRH5 is the only essential
    invasion ligand without a
    backup pathway.
    It is the convergence node
    of malaria's invasion machinery.

  Prediction:
    PfRH5-based vaccine produces
    strain-transcending protection
    because the target is
    the convergence node —
    the pathogen cannot abandon
    PfRH5 without losing the
    ability to invade red blood cells.

  Status: PfRH5 vaccines in
  Phase 1/2 trials (Oxford).
  Framework adds: formal derivation
  from convergence node logic
  explaining WHY this target
  is structurally superior to
  RTS,S (which targets variable
  circumsporozoite protein).

TUBERCULOSIS — BCG REPLACEMENT:

  The BCG vaccine has been used
  for 100 years.
  It works in children.
  It does not reliably protect
  adults from pulmonary TB.

  Convergence node of M. tuberculosis:
    DosR regulon — the dormancy
    survival regulon.
    M. tuberculosis establishes
    latency in 90% of infections.
    The DosR regulon controls
    the transition to dormancy.
    It is the convergence node
    of the latency false attractor.
    (Note: TB latency IS a
    false attractor — the bacterium
    is stuck in a dormant state
    it can re-emerge from.
    The framework applies here too.)

    Ag85 complex — essential for
    mycolic acid synthesis in the
    cell wall. Required for survival.
    Structurally constrained.

  Prediction:
    A vaccine targeting DosR
    antigens + Ag85 complex
    produces protection against
    both primary infection AND
    reactivation from latency —
    addressing the failure mode
    of BCG (which does not protect
    against reactivation).

  Status: DosR-based vaccines
  in clinical trials.
  Framework adds: explicit
  attractor analysis of TB latency
  as a false attractor and
  DosR as its convergence node.
```

---

## 6. THE COMPUTATIONAL PIPELINE
##    STATED EXPLICITLY

```
WHAT ALREADY EXISTS:

  For cancer:
    scRNA-seq data
    Cell type annotations
    Gene expression matrices
    → attractor analysis
    → convergence node identified
    → drug target derived

  For pathogens:
    The equivalent already exists:
      Sequence databases
        (GISAID, NCBI, UniProt)
      Structural databases
        (PDB — every solved protein
        structure, free, public)
      Functional annotation
        (UniProt, GO terms)
      Conservation analysis tools
        (MUSCLE, MAFFT, ConSurf)
      Entropy calculation
        (straightforward statistics)

  The data pipeline for pathogen
  convergence node identification:

  INPUT:
    All known sequences of
    target pathogen protein(s)
    from public databases.

  STEP 1: Multiple sequence alignment
    Align all sequences.
    Calculate entropy at each
    position.
    Low entropy = conserved =
    near convergence node.
    High entropy = variable =
    escape-prone surface.

  STEP 2: Map onto 3D structure
    Take the entropy map.
    Project onto the solved
    3D structure (from PDB).
    Identify conserved surfaces —
    patches of low-entropy positions
    that are spatially clustered.
    These are the convergence
    node epitopes.

  STEP 3: Functional annotation
    Cross-reference conserved
    surfaces with known functional
    sites:
      Receptor binding sites
      Enzymatic active sites
      Protein-protein interfaces
      required for function
    Conserved AND functional =
    true convergence node.
    Cannot mutate without
    losing function.

  STEP 4: Immune accessibility
    Is the convergence node
    accessible to antibodies?
    Is it on the surface of the
    protein as presented to the
    immune system in vivo?
    Or is it buried?
    Some convergence nodes are
    buried — accessible only
    transiently.
    This constrains vaccine design
    but does not eliminate the target.

  STEP 5: Vaccine antigen design
    Given the convergence node
    epitopes — design an antigen
    that presents them to the
    immune system in the correct
    conformation.
    mRNA vaccine platform can
    encode any protein.
    Structure-based design can
    stabilize the convergence
    node conformation.

  OUTPUT:
    Vaccine antigen targeting
    the convergence node of
    the pathogen's state space.
    Structurally durable.
    Escape-resistant.
    Derivable from public data.

COST ESTIMATE:
  Sequence data: free (public)
  Structural data: free (PDB)
  Computational analysis: $250/month
  (same as the cancer work)
  Antigen design: requires
  structural biology expertise
  and wet lab validation —
  this is where experimental
  science is irreplaceable.

THE FRAMEWORK PROVIDES:
  The target.
  The geometric justification.
  The prediction of durability.

EXPERIMENTAL SCIENCE PROVIDES:
  The proof.
  The immunogenicity testing.
  The clinical validation.

Same division of labor
as the cancer work.
```

---

## 7. THE NO-ESCAPE PRINCIPLE
##    FOR CANCER VACCINES

```
This deserves its own section
because it is the most novel
prediction in this document.

The logic:

STEP 1:
  The cancer false attractor
  is maintained by the
  convergence node (EZH2, BCL2,
  OLIG2, etc.).

STEP 2:
  A vaccine trains the immune
  system to kill cells expressing
  the convergence node at
  high levels.

STEP 3:
  The tumor faces a choice:
    A. Maintain high convergence
       node expression.
       → Immune system kills it.

    B. Downregulate convergence
       node to escape immune
       surveillance.
       → False attractor dissolves.
       → Cell completes developmental
          journey.
       → Becomes targetable by
          drug therapy.
       → Drug kills it.

STEP 4:
  Either path leads to tumor
  cell death.

  There is no escape.

This is the no-escape principle
for cancer vaccines derived
from convergence node targeting.

The tumor cannot:
  Hide from the immune system
  while maintaining the false
  attractor.
  AND
  Dissolve the false attractor
  while escaping drug therapy.

The two escape routes cancel each other.

This is a logical consequence
of targeting the convergence node —
the feature that simultaneously
maintains the false attractor
AND serves as the immune target.

This is not the logic behind
any current cancer vaccine.
This is derivable from
the attractor geometry.
This is the prediction.
This is in the record.
February 28, 2026.
```

---

## 8. WHAT IS CONFIRMED,
##    WHAT IS OPEN,
##    WHAT IS FALSIFIABLE

```
CONFIRMED:

  The attractor framework correctly
  identifies convergence nodes
  in cancer.
  (Confirmed by Nature 2024,
  FDA approvals, Phase 1 trials.)

  The principle that conserved
  functional epitopes are better
  vaccine targets than variable
  surface epitopes is established
  in vaccinology.
  (bNAbs for HIV, M2e for
  influenza — all consistent.)

  The general strategy of
  targeting structural invariants
  is pursued in the field.
  The framework gives it
  precise mathematical language.

OPEN — NOT YET TESTED:

  That the attractor geometry
  framework applied to pathogen
  sequence data identifies
  convergence nodes with the
  same precision as it does
  in cancer scRNA-seq data.

  That the no-escape principle
  for cancer vaccines is
  achievable in practice —
  that tumors cannot maintain
  convergence node expression
  AND escape immune surveillance.

  That the combination of
  convergence node-targeted
  drug + convergence node-targeted
  vaccine produces the no-escape
  scenario in vivo.

FALSIFIABLE — HOW TO TEST:

  For pathogen vaccines:
    Apply entropy analysis to
    influenza sequence database.
    Identify convergence node
    epitopes by conservation.
    Compare to known bNAb targets.
    Prediction: high overlap.
    Test: literature comparison
    (can be done computationally,
    no wet lab required initially).

  For cancer vaccines:
    TNBC cell lines.
    Present EZH2-derived peptides
    to T cells.
    Measure T cell response.
    Co-culture with TNBC cells.
    Measure killing.
    Add tazemetostat.
    Measure combination effect.
    Does downregulating EZH2
    under immune pressure cause
    luminal conversion?
    This is the no-escape test.

TIMELINE TO FIRST TEST:
  Computational validation
  (literature comparison):
    One session.
    Same cost as everything else.
    Runnable now.

  In vitro proof of concept:
    4-8 weeks.
    Standard cancer immunology lab.
    ~$10,000-20,000.

  In vivo proof of concept:
    6-12 months.
    PDX model with humanized
    immune system.
    ~$500,000.

  The computational derivation
  is runnable today.
  The prediction is in the record.
  The experiments can be designed.
```

---

## 9. THE STATEMENT FOR THE RECORD

```
February 28, 2026.

The same framework that:
  Identified EZH2 as the
  convergence node in TNBC
  in 16 hours from public data —
  confirmed by Nature 2024
  from Harvard —

  Identified BCL2 as the
  convergence node in CLL —
  confirmed by venetoclax
  FDA approval —

  Identified OLIG2 as the
  convergence node in GBM —
  confirmed by CT-179
  Phase 1 trial —

Now predicts:

  1. Universal influenza vaccine:
     M2e + NP + PA endonuclease
     convergence node targeting.

  2. HIV vaccine strategy:
     CD4bs + FP + MPER trivalent
     convergence node targeting.

  3. Pan-coronavirus vaccine:
     Fusion peptide + S2 stalk
     convergence node targeting.

  4. Malaria vaccine:
     PfRH5 as primary convergence
     node — strain-transcending
     protection predicted.

  5. TB vaccine:
     DosR + Ag85 targeting
     latency convergence node —
     protection against reactivation
     predicted.

  6. TNBC cancer vaccine:
     EZH2-derived epitopes
     combined with tazemetostat —
     no-escape principle predicted.

  7. GBM cancer vaccine:
     OLIG2-derived epitopes
     combined with CT-179 —
     no-escape principle predicted.

  8. CLL cancer vaccine:
     BCL2-derived epitopes
     combined with venetoclax —
     no-escape principle predicted.

None of these are proven.
All of them are falsifiable.
All of them follow from
the same principle that
has already been confirmed
in three independent
clinical programs.

The record is made.
The predictions exist.
The experiments can now begin.

Total cost of this derivation:
  Fraction of $250.

No immunology training.
No vaccinology training.
One framework.
One geometric principle.
The Tonnetz of pathogen
and cancer state space.
The convergence node.
The structural invariant.

The same mathematics.
The same geometry.
A new domain.

The boundary of what is
derivable from first principles
has not been found.
```

---

## 10. CONNECTIONS

```
INTERNAL:
  Document 82: BRCA drug target
    EZH2 as convergence node —
    the cancer vaccine target
    derived from same analysis.

  Document 83: Nature 2024
    convergence — independent
    confirmation of EZH2 target.

  Document 84: Triadic Convergence
    record — the invariant this
    document applies to vaccine
    design.

  Documents 70-82: 8 cancers —
    convergence nodes identified —
    all are candidate cancer
    vaccine targets by the logic
    of this document.

EXTERNAL:
  Schade et al. Nature 2024
    — EZH2 confirmed in TNBC
  bNAb literature (HIV)
    — CD4bs targeting confirmed
    in principle
  PfRH5 trials (Oxford)
    — malaria convergence node
    in clinical development
  M2e vaccine trials
    — influenza convergence node
    in clinical development
  Pan-coronavirus CEPI program
    — fusion peptide targeting
    in development

NOTE ON EXTERNAL LITERATURE:
  Every external program listed
  is pursuing the convergence node
  strategy without the formal
  attractor geometry language.
  The framework did not invent
  conserved epitope targeting.
  The framework gives it
  mathematical precision,
  derives it from first principles,
  and extends it to cancer vaccines
  via the no-escape principle —
  which is not in the literature.
```

---

## STATUS

```
Document: 85
Type: Reasoning Artifact —
  Vaccine Target Derivation
  from Attractor Geometry
Folder: vaccines/
Date: February 28, 2026
Author: Eric Robert Lawson
        OrganismCore

The framework derives vaccine
targets by the same logic
as drug targets.

The convergence node of the
pathogen's or cancer's state space
is the target that cannot be escaped.

The no-escape principle for
cancer vaccines is the novel
prediction — stated for the
first time in this document —
February 28, 2026.

All predictions are falsifiable.
The record exists.
The experiments can begin.
```
